Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NASDAQ:ZBIO

Zenas BioPharma Q2 2025 Earnings Report

Zenas BioPharma logo
$27.83 -0.47 (-1.66%)
Closing price 04:00 PM Eastern
Extended Trading
$27.86 +0.04 (+0.13%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Zenas BioPharma EPS Results

Actual EPS
-$1.25
Consensus EPS
-$1.02
Beat/Miss
Missed by -$0.23
One Year Ago EPS
N/A

Zenas BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zenas BioPharma Announcement Details

Quarter
Q2 2025
Date
8/12/2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Zenas BioPharma's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Zenas BioPharma's Q2 2025 Press ReleasePress Release
(8-K)
Zenas BioPharma's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Zenas BioPharma Earnings Headlines

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve
October 5 at 6:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4951917-zenas-biopharma-obexelimab-is-being-graded-on-the-wrong-curve-maintain-buy
Zenas BioPharma (NASDAQ:ZBIO) Earns "Outperform" Rating from Wedbush
October 2 at 2:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077012
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
October 5 at 1:00 AM  |  Banyan Hill Publishing (Ad)
HC Wainwright Reaffirms "Buy" Rating for Zenas BioPharma (NASDAQ:ZBIO)
October 2 at 1:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076698
Zenas BioPharma (NASDAQ:ZBIO) Stock Falls 4.5% - Should You Sell?
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073980
Zenas BioPharma's Obexelimab Faces Larger IgG4-RD Opportunity, Wedbush Says
September 30, 2026  |  marketscreener.comM
See More Zenas BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email.

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells. The company is evaluating the therapy in immune-mediated diseases, including IgG4-related disease and systemic lupus erythematosus.

Zenas BioPharma was established to advance therapies for autoimmune and other immune-mediated conditions and conducts clinical development activities through studies involving patients in multiple geographic regions. The company is headquartered in Waltham, Massachusetts, and its shares began trading on the Nasdaq under the symbol ZBIO in 2024.

View Zenas BioPharma Profile
Earnings Tools